QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A8AB09FA390A3AE4E0D1D6F38BF237B8;jsessionid=51586F57457820B19218871CCD1B1B0A;jsessionid=1378266A38B81A4711AC8DCC93F77B7F;jsessionid=73AC8971AD1AC6EB5D00E04011873BA7;jsessionid=C057DE3D41D9400A19D1CA708AC75D4C;jsessionid=8024CB861F67EABF3542FC05E9ADF376;jsessionid=E6E189B5D4EC9EA760E7188A55E488D8;jsessionid=0261BC4AFCC1CD47DE490D3A19507779;jsessionid=EB7C55654AA36194FCB5CC57F4DFF591;jsessionid=563BD07F7ED8F814697406461E5DD974;jsessionid=3CE049923155C6867F045750B02E790A;jsessionid=C3A97B4C38C60DFEB6E36E5F6D246982;jsessionid=503E3AAF17A0E00FA2120488CCE3ABA8;jsessionid=59F95456169EEE7E2D043F77F65B7750;jsessionid=403C65312A63DC52649D8E73AFA32A4B (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease.
3. Clinical features, disease progression, and nuclear imaging in ATXN2-related parkinsonism in a longi…
4. ATXN2 is a target of N-terminal proteolysis.
5. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A8AB09FA390A3AE4E0D1D6F38BF237B8;jsessionid=51586F57457820B19218871CCD1B1B0A;jsessionid=1378266A38B81A4711AC8DCC93F77B7F;jsessionid=73AC8971AD1AC6EB5D00E04011873BA7;jsessionid=C057DE3D41D9400A19D1CA708AC75D4C;jsessionid=8024CB861F67EABF3542FC05E9ADF376;jsessionid=E6E189B5D4EC9EA760E7188A55E488D8;jsessionid=0261BC4AFCC1CD47DE490D3A19507779;jsessionid=EB7C55654AA36194FCB5CC57F4DFF591;jsessionid=563BD07F7ED8F814697406461E5DD974;jsessionid=3CE049923155C6867F045750B02E790A;jsessionid=C3A97B4C38C60DFEB6E36E5F6D246982;jsessionid=503E3AAF17A0E00FA2120488CCE3ABA8;jsessionid=59F95456169EEE7E2D043F77F65B7750;jsessionid=403C65312A63DC52649D8E73AFA32A4B